Empirical Asset Management, LLC Akebia Therapeutics, Inc. Transaction History
Empirical Asset Management, LLC
- $3.46 Billion
- Q4 2024
A detailed history of Empirical Asset Management, LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Empirical Asset Management, LLC holds 13,300 shares of AKBA stock, worth $27,530. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,300
Previous 33,700
60.53%
Holding current value
$27,530
Previous $44,000
45.45%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding AKBA
# of Institutions
120Shares Held
54.8MCall Options Held
291KPut Options Held
179K-
Black Rock Inc. New York, NY11.6MShares$24.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$20.8 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$11.9 Million13.23% of portfolio
-
Geode Capital Management, LLC Boston, MA4.75MShares$9.84 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.72MShares$7.7 Million0.01% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $381M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...